Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Hepatoblastoma 1

Interventions

Cyclophosphamide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Nuclear Medicine Department, Hospital 4Carboplatin 4fludarabine 3Temozolomide 3Nivolumab 3Gemcitabine 3Filgrastim 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2belinostat 2Vemurafenib 2Topotecan 2Psychiatric Rehabilitation 2Oxaliplatin 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × GRN163L peptide × Gastrointestinal × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡